Inhibrx's chart data is dated 2026-10-08. There is no active technical signal. There are 2 published signal records.
Inhibrx last closed at $92.76 (-0.64%) on 2026-10-08. Listed on Nasdaq. Trailing 12 months PER is -10.5×. Its overall grade ranks 37 of 738 stocks in Healthcare.
About this company
Inhibrx last closed at $92.76 (-0.64%) on 2026-10-08. Listed on Nasdaq.
Details →Reported results
Position in sector
Healthcare · Overall A+ · 37/738
Valuation grade A+
Related stocks
- SanofiCustomer
알파-1 항트립신(AAT) 계열 자산을 둘러싼 전략적 인수·협력 관계가 있어 핵심 이해관계자
- Vertex PharmaceuticalsCompetitor
알파-1 항트립신 결핍증(AATD) 및 면역·희귀질환 치료제 개발 영역에서 경쟁 가능성이 큼
- Madrigal PharmaceuticalsCompetitor
희귀·만성질환 치료제 개발사로 파이프라인/자본시장 관점에서 유사한 바이오 경쟁군
About Inhibrx
- What technical signals does Inhibrx (INBX) have?
- Inhibrx current technical signals: no active technical signal.
- Is Inhibrx a cup-and-handle pattern?
- No. Inhibrx has no valid Cup signal right now.
- What published figures are available for Inhibrx?
- Trailing 12 months PER: -10.5×. Latest quarter PBR: -27.44×. Dividend yield: 0.00%.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Major stocks in the same sector
2026-10-09 dataset
Turn what you saw on this name into a strategy
Ask Q about Inhibrx, or open the plan table on the main site.
From the names you found to a trading rule
Tell Q about the stocks you found to place orders with your conditions.